Kodiak Sciences Inc
KOD7.272USD
+0.623+9.36%
시장 운영 시간 （ET）시세는 15분 지연됩니다
383.64M시가총액
손실P/E TTM
자세한 내용은 Kodiak Sciences Inc 회사
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
회사 정보
종목 코드 KOD
회사 이름Kodiak Sciences Inc
상장일Oct 04, 2018
CEODr. Victor Perlroth, M.D.
직원 수109
유형Ordinary Share
회계 연도 종료Oct 04
주소1250 Page Mill Road
도시PALO ALTO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94304
전화16502810850
웹사이트https://kodiak.com/
종목 코드 KOD
상장일Oct 04, 2018
CEODr. Victor Perlroth, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
주주
주주
비율
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
주주 유형
주주
비율
Hedge Fund
46.97%
Investment Advisor
18.19%
Investment Advisor/Hedge Fund
13.56%
Individual Investor
5.53%
Research Firm
1.50%
Endowment Fund
1.31%
Pension Fund
0.18%
Venture Capital
0.09%
Bank and Trust
0.07%
Other
12.61%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
273
46.04M
87.25%
-8.22M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
2023Q1
414
44.84M
85.66%
-7.92M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Baker Bros. Advisors LP
17.31M
32.81%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.37%
-21.30K
-0.75%
Mar 31, 2025
Perlroth (Victor D)
2.70M
5.11%
+527.00K
+24.31%
Mar 31, 2025
Acadian Asset Management LLC
1.95M
3.69%
+413.82K
+27.01%
Mar 31, 2025
The Vanguard Group, Inc.
1.69M
3.2%
+6.61K
+0.39%
Mar 31, 2025
Adage Capital Management, L.P.
1.33M
2.51%
+186.18K
+16.34%
Mar 31, 2025
ICONIQ Capital, LLC
1.27M
2.4%
+249.70K
+24.56%
Mar 31, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.07M
2.03%
+548.67K
+104.76%
Mar 31, 2025
Boxer Capital Management, LLC
1.03M
1.96%
+35.00K
+3.50%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
ProShares UltraPro Russell2000
0%
Vanguard US Momentum Factor ETF
0%
더 보기
Fidelity Enhanced Small Cap ETF
비율0.04%
iShares Micro-Cap ETF
비율0.03%
Avantis US Small Cap Equity ETF
비율0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0.01%
Invesco RAFI US 1500 Small-Mid ETF
비율0.01%
Schwab U.S. Small-Cap ETF
비율0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Vanguard US Momentum Factor ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
